source
- Merck sees pivotal victory for $3B eye disease prospectMerck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
- Sarepta Therapeutics agrees to pay $39 million to settle gene therapy dispute with RegenxbioSarepta Therapeutics has agreed to resolve a dispute with Regenxbio by paying $39 million. The payment settles claims related to gene therapy technology that both companies have been developing.…